IV Arsenic Trioxide
Phase 3Small molecule
IV Arsenic Trioxide is one of 2 small molecule programs targeting Arsenic Trioxide. It is currently in Phase 3.
1
Indications
1
Total Trials
1
Active Trials
1
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
1 competitor in Arsenic Trioxide
#DrugCompanyPhaseTrials
1ALL-Trans Retinoic Acid (ATRA)
IncytePhase 3
IV Arsenic Trioxide
SSDK Therapeutics, Inc.
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for IV Arsenic Trioxide. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- SSDK Therapeutics, Inc.